{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:29:02Z","timestamp":1648600142027},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T00:00:00Z","timestamp":1484611200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00393-016-0258-0","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T08:48:29Z","timestamp":1484642909000},"page":"27-32","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ausschleichen und Beenden von immunsuppressiven Therapien"],"prefix":"10.1007","volume":"76","author":[{"given":"M.","family":"Aringer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Leuchten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fischer-Betz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,17]]},"reference":[{"key":"258_CR1","first-page":"71","volume":"31","author":"M Mosca","year":"2013","unstructured":"Mosca M, Tani C, Aringer M (2013) Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal? Clin Exp Rheumatol 31:71\u2013S74","journal-title":"Clin Exp Rheumatol"},{"key":"258_CR2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","volume":"340","author":"DT Boumpas","year":"1992","unstructured":"Boumpas DT, Austin HA III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH et\u00a0al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741\u2013745","journal-title":"Lancet"},{"key":"258_CR3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","volume":"324","author":"The Canadian Hydroxychloroquine Study Group","year":"1991","unstructured":"The Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324:150\u2013154","journal-title":"N Engl J Med"},{"key":"258_CR4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.7326\/0003-4819-119-5-199309010-00003","volume":"119","author":"DT Boumpas","year":"1993","unstructured":"Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366\u2013369","journal-title":"Ann Intern Med"},{"key":"258_CR5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/rheumatology\/keu372","volume":"54","author":"M Faurschou","year":"2015","unstructured":"Faurschou M, Mellemkjaer L, Voss A, Keller KK, Hansen IT, Baslund B (2015) Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Rheumatology (Oxford) 54:1345\u20131350","journal-title":"Rheumatology (Oxford)"},{"key":"258_CR6","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","volume":"350","author":"G Contreras","year":"2004","unstructured":"Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O\u2019Nan P et\u00a0al (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971\u2013980","journal-title":"N Engl J Med"},{"key":"258_CR7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D, Sebastiani GD, de Ramon GE, Danieli MG et al (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69:61\u201364","journal-title":"Ann Rheum Dis"},{"key":"258_CR8","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH et al (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771\u20131782","journal-title":"Ann Rheum Dis"},{"key":"258_CR9","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/TP.0b013e3181952623","volume":"87","author":"SR Knight","year":"2009","unstructured":"Knight SR, Russell NK, Barcena L, Morris PJ (2009) Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a\u00a0systematic review. Transplantation 87:785\u2013794","journal-title":"Transplantation"},{"key":"258_CR10","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.transproceed.2015.03.039","volume":"47","author":"B Aguiar","year":"2015","unstructured":"Aguiar B, Santos AT, Romaozinho C, Santos L, Macario F, Alves R et al (2015) Malignancy in kidney transplantation: A\u00a025-year single-center experience in Portugal. Transplant Proc 47:976\u2013980","journal-title":"Transplant Proc"},{"key":"258_CR11","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","volume":"365","author":"MA Dooley","year":"2011","unstructured":"Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D et\u00a0al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365:1886\u20131895","journal-title":"N Engl J Med"},{"key":"258_CR12","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D et\u00a0al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J\u00a0Am Soc Nephrol 20:1103\u20131112","journal-title":"J Am Soc Nephrol"},{"key":"258_CR13","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.ki.5001630","volume":"70","author":"C Grootscholten","year":"2006","unstructured":"Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M et al (2006) Azathioprine\/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A\u00a0randomized controlled trial. Kidney Int 70:732\u2013742","journal-title":"Kidney Int"},{"key":"258_CR14","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/rheumatology\/kes425","volume":"52","author":"R Fischer-Betz","year":"2013","unstructured":"Fischer-Betz R, Specker C, Brinks R, Aringer M, Schneider M (2013) Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford) 52:1070\u20131076","journal-title":"Rheumatology (Oxford)"},{"key":"258_CR15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.2007.070367","volume":"67","author":"G Bertsias","year":"2008","unstructured":"Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C et\u00a0al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a\u00a0Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67:195\u2013205","journal-title":"Ann Rheum Dis"},{"key":"258_CR16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/art.25052","volume":"62","author":"EM Ginzler","year":"2010","unstructured":"Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA (2010) Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a\u00a0multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 62:211\u2013221","journal-title":"Arthritis Rheum"},{"key":"258_CR17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00393-010-0687-0","volume":"70","author":"G Keysser","year":"2011","unstructured":"Keysser G (2011) Methotrexate toxicity. Myths and facts. Z Rheumatol 70:108\u2013113","journal-title":"Z Rheumatol"},{"key":"258_CR18","first-page":"65","volume":"28","author":"Y Yazici","year":"2010","unstructured":"Yazici Y (2010) Long-term safety of methotrexate in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 28:65\u2013S67","journal-title":"Clin Exp Rheumatol"},{"key":"258_CR19","first-page":"156","volume":"28","author":"M Winzer","year":"2010","unstructured":"Winzer M, Aringer M (2010) Use of methotrexate in patients with systemic lupus erythematosus and primary Sjogren\u2019s syndrome. Clin Exp Rheumatol 28:156\u2013S159","journal-title":"Clin Exp Rheumatol"},{"key":"258_CR20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a\u00a0randomised, placebo-controlled, phase 3 trial. Lancet 377:721\u2013731","journal-title":"Lancet"},{"key":"258_CR21","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D et al (2011) A\u00a0phase III, randomized, placebo-controlled study of belimumab, a\u00a0monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918\u20133930","journal-title":"Arthritis Rheum"},{"key":"258_CR22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3899\/jrheum.121368","volume":"41","author":"EM Ginzler","year":"2014","unstructured":"Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW et\u00a0al (2014) Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J\u00a0Rheumatol 41:300\u2013309","journal-title":"J Rheumatol"},{"key":"258_CR23","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/0961203315625119","volume":"25","author":"IN Bruce","year":"2016","unstructured":"Bruce IN, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M et al (2016) Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus 25:699\u2013709","journal-title":"Lupus"},{"key":"258_CR24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/0961203311426569","volume":"21","author":"M Aringer","year":"2012","unstructured":"Aringer M, Burkhardt H, Burmester GR, Fischer-Betz R, Fleck M, Graninger W et al (2012) Current state of evidence on \u2019off-label\u2019 therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland\u2013a consensus report. Lupus 21:386\u2013401","journal-title":"Lupus"},{"key":"258_CR25","doi-asserted-by":"crossref","first-page":"e000163","DOI":"10.1136\/lupus-2016-000163","volume":"3","author":"M Ryden-Aulin","year":"2016","unstructured":"Ryden-Aulin M, Boumpas D, Bultink I, Callejas Rubio JL, Caminal-Montero L, Castro A et al (2016) Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med 3:e000163","journal-title":"Lupus Sci Med"},{"key":"258_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22921","author":"R Aguiar","year":"2016","unstructured":"Aguiar R, Araujo C, Martins-Coelho G, Isenberg D (2016) Use of rituximab in systemic lupus erythematosus: a\u00a0single center experience over 14 years. Arthritis Care Res (Hoboken). doi: 10.1002\/acr.22921","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"258_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22993","author":"V Reddy","year":"2016","unstructured":"Reddy V, Martinez L, Isenberg DA, Leandro MJ, Cambridge G (2016) Pragmatic treatment of patients with Systemic Lupus Erythematosus with rituximab: Long-term effects on serum immunoglobulins. Arthritis Care Res (Hoboken). doi: 10.1002\/acr.22993","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"258_CR28","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF Vollenhoven van","year":"2015","unstructured":"van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB (2015) Longterm safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 years. J\u00a0Rheumatol 42:1761\u20131766","journal-title":"J Rheumatol"},{"issue":"2","key":"258_CR29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2014.04.002","volume":"44","author":"T Cobo-Ibanez","year":"2014","unstructured":"Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, Marques AO, Rua-Figueroa I, Fernandez-Nebro A et al (2014) Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A\u00a0systematic review. Semin Arthritis Rheum 44(2):175\u2013185","journal-title":"Semin Arthritis Rheum"},{"key":"258_CR30","first-page":"449","volume":"33","author":"L Iaccarino","year":"2015","unstructured":"Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, de Vita S et al (2015) Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin Exp Rheumatol 33:449\u2013456","journal-title":"Clin Exp Rheumatol"},{"key":"258_CR31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","volume":"82","author":"R Cervera","year":"2003","unstructured":"Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al (2003) Morbidity and mortality in systemic lupus erythematosus during a\u00a010-year period: a\u00a0comparison of early and late manifestations in a\u00a0cohort of 1,000 patients. Medicine (Baltimore) 82:299\u2013308","journal-title":"Medicine (Baltimore)"},{"key":"258_CR32","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386\u20131394","journal-title":"Ophthalmology"},{"key":"258_CR33","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1016\/j.lpm.2014.03.007","volume":"43","author":"N Costedoat-Chalumeau","year":"2014","unstructured":"Costedoat-Chalumeau N, Dunogue B, Morel N, Le Guern V, Guettrot-Imbert G (2014) Hydroxychloroquine: a\u00a0multifaceted treatment in lupus. Presse Med 43:e167\u2013e180","journal-title":"Presse Med"},{"key":"258_CR34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/0961203307086643","volume":"17","author":"G Ruiz-Irastorza","year":"2008","unstructured":"Ruiz-Irastorza G, Khamashta MA (2008) Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 17:271\u2013273","journal-title":"Lupus"},{"issue":"Suppl 2","key":"258_CR35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/annrheumdis-2015-eular.6698","volume":"74","author":"RF Vollenhoven van","year":"2015","unstructured":"van Vollenhoven RF, Aranow C, Bertsias G, Bonfa E, Cervera R, Costedoat-Chalumeau N, D\u00f6rner T, Houssiau F, Lertsrom K, Moran E, Mosca M, Navarra S, Petri M, Urowitz M, Voskuijl A, Voss A, Ward M, Werth V, Schneider M (2015) Remission in SLE: Consensus findings from a\u00a0large international panel on definitions of remission in SLE (DORIS). Ann Rheum Dis 74(Suppl 2):103 (Abstract)","journal-title":"Ann Rheum Dis"},{"key":"258_CR36","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","volume":"68","author":"D Huscher","year":"2009","unstructured":"Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R et al (2009) Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 68:1119\u20131124","journal-title":"Ann Rheum Dis"},{"key":"258_CR37","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/rheumatology\/keu148","volume":"53","author":"I Ruiz-Arruza","year":"2014","unstructured":"Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina JA, Moran MA, Ruiz-Irastorza G (2014) Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 53:1470\u20131476","journal-title":"Rheumatology (Oxford)"},{"key":"258_CR38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/RHU.0000000000000335","volume":"22","author":"FB Moya","year":"2016","unstructured":"Moya FB, Pineda Galindo LF, Garc\u00eda de la Pe\u00f1a M (2016) Impact of chronic glucocorticoid treatment on cardiovascular risk profile in patients with Systemic Lupus Erythematosus. J\u00a0Clin Rheumatol 22:8\u201312","journal-title":"J Clin Rheumatol"},{"key":"258_CR39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","volume":"52","author":"J Listing","year":"2013","unstructured":"Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 52:53\u201361","journal-title":"Rheumatology (Oxford)"},{"key":"258_CR40","doi-asserted-by":"crossref","first-page":"e000098","DOI":"10.1136\/lupus-2015-000098","volume":"3","author":"L Carli","year":"2016","unstructured":"Carli L, Tani C, Spera V, Vagelli R, Vagnani S, Mazzantini M et\u00a0al (2016) Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. Lupus Sci Med 3:e000098","journal-title":"Lupus Sci Med"},{"issue":"Suppl 2","key":"258_CR41","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/annrheumdis-2016-eular.2560","volume":"75","author":"C Tani","year":"2016","unstructured":"Tani C, Carli L, Vagelli R, Signorini V, Vagnani S, Totti D, Tristano M, Mosca M (2016) Glucocorticoids withdrawal in systemic lupuserythematosus: myth or reality? Ann Rheum Dis 75(Suppl 2):290 (Abstract)","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-016-0258-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-016-0258-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-016-0258-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T08:24:40Z","timestamp":1498379080000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-016-0258-0"}},"subtitle":["Systemischer Lupus erythematodes"],"short-title":[],"issued":{"date-parts":[[2017,1,17]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["258"],"URL":"https:\/\/doi.org\/10.1007\/s00393-016-0258-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,17]]}}}